Rac1 regulation of surface expression of protease-activated receptor-1 and responsiveness to thrombin in vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 7, 2005, Pages 1506-1511

  Yufu, Tatsuya ^a   Hirano, Katsuya ^a   Bi, Dan ^a   Hirano, Mayumi ^a   Nishimura, Junji ^a   Iwamoto, Yukihide ^a   Kanaide, Hideo ^b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Expression; Protease activated receptor; Rac1; Smooth muscle; Thrombin

Indexed keywords

CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN CDC42; PROTEINASE ACTIVATED RECEPTOR 1; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; THROMBIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; ISOPRENYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CALCIUM; CELLS, CULTURED; CORONARY VESSELS; DOWN-REGULATION; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SMOOTH, VASCULAR; PROTEIN ISOPRENYLATION; RAC1 GTP-BINDING PROTEIN; RATS; RECEPTOR, PAR-1; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIMVASTATIN; THROMBIN;

EID: 21544456653     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000168418.10276.f0     Document Type: Article

References (36)

1. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature. 2000;407:258-264.
2. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274:C1429-C1452.
3. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev. 2002;54: 203-217.
4. Macfarlane SR, Scatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
5. Schmidlin F, Bunnett NW. Protease-activated receptors: how proteases signal to cells. Curr Opin Pharmacol. 2001;1:575-582.
6. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003;10:211-225.
7. Noorbakhsh F, Vergnolle N, Hollenberg MD, Power C. Proteinase-activated receptors in the nervous system. Nat Rev Neurosci. 2003;4: 981-990.
8. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84:579-621.
9. Rohatgi T, Henrich-Noack P, Sedehizade P, Goertler M, Wallesch CW, Reymann KG, Reiser G. Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4. J Neurosci Res. 2004;75:273-279.
10. Ku DD, Dai J. Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro. J Cardiovasc Pharmacol. 1997;30:649-657.
11. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
12. Wilcox J, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer D, Horaist C, Hanson S, Lumsden A, Salam T. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038.
13. Shapiro MJ, Coughlin SR. Separate signals for agonist-independent and agonist-triggered trafficking of protease-activated receptor 1. J Biol Chem. 1998;273:29009-29014.
14. Trejo J. Protease-activated receptors: new concepts in regulation of G-protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther. 2003;307:437-442.
15. Marchese A, Chen C, Kim YM, Benovic JL. The ins and outs of G-protein-coupled receptor trafficking. Trends Biochem Sci. 2003;28:369-376.
16. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153-208.
17. Seachrist JL, Ferguson SS. Regulation of G-protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci. 2003;74:225-235.
18. Roosterman D, Schmidlin F, Bunnett NW. Rab5a and rab11a mediate agonist-induced trafficking of protease-activated receptor 2. Am J Physiol. 2003;284:C1319-C1329.
19. Izumi G, Sakisaka T, Baba T, Tanaka S, Morimoto K, Takai Y. Endocytosis of E-cadherin regulated by Rac and Cdc42 small G-proteins through IQGAP1 and actin filaments. J Cell Biol. 2004;166:237-248.
20. Rochdi MD, Laroche G, Dupre E, Giguere P, Lebel A, Watier V, Hamelin E, Lepine M-C, Dupuis G, Parent J-L. Nm23-H2 interacts with a G-protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J Biol Chem 2004;279:18981-18989.
21. Tkachenko E, Lutgens E, Stan R-V, Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci. 2004;117:3189-3199.
22. Wherlock M, Gampel A, Futter C, Mellor H. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J Cell Sci 2004;117:3221-3231.
23. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32:164-176.
24. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;10:143-148.
25. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287.
26. Hirano K, Hirano M, Nishimura J, Kanaide H. A critical period requiring Rho proteins for cell cycle progression uncovered by reversible protein transduction in endothelial cells. FEBS Lett. 2004;570:149-154.
27. 2+ sensitivity in an intact coronary artery. Arterioscler Thromb Vasc Biol. 2004;24:464-469.
28. Koga M, Hirano K, Hirano M, Nishimura J, Nakano H, Kanaide H. Akt plays a central role in the anti-apoptotic effect of estrogen in endothelial cells. Biochem Biophys Res Commun. 324:321-325.
29. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99-103.
30. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 2000;10:290-295.
31. 1 phase is controlled by Rho. Nat Cell Biol. 2001;3:950-957.
32. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-1062.
33. Nakayama T, Hirano K, Hirano M, Nishimura J, Kuga H, Nakamura K, Takahashi S, Kanaide H. Inacttvation of protease-activated receptor-1 by proteolytic removal of the ligand region in vascular endothelial cells. Biochem Pharmacol. 2004;68:23-32.
34. Shapiro MJ, Trejo J, Zeng D, Coughlin SR. Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. J Biol Chem. 1996;271:32874-32880.
35. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004; 116:167-179.
36. 1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem. 1997;272:13-16.